TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32359757

Group type: EXPERIMENTAL
Intervention: High phase angle derived from bioelectrical impedance analysis (Nutriguard®).
Number of subjects: 2264
Study: 32359931

Group type: EXPERIMENTAL
Intervention: Plant-sourced cooking oils (highest tertile consumption)
Number of subjects: 14305

Group type: EXPERIMENTAL
Intervention: Replacing animal cooking oils with 1 tablespoon/d of total plant cooking oils
Number of subjects: 14305

Group type: EXPERIMENTAL
Intervention: Replacing animal cooking oils with 1 tablespoon/d of other plant cooking oils
Number of subjects: 14305

Group type: EXPERIMENTAL
Intervention: Peanut oil or salad oil consumption in replacement of animal cooking oils
Number of subjects: 14305
Study: 32360168

Group type: EXPERIMENTAL
Intervention: Dynamic faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic objects
Number of subjects: 0
Study: 32360681

Group type: EXPERIMENTAL
Intervention: TAMBE endograft
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: TAMBE combined with GORE CTAG proximal thoracic stent graft
Number of subjects: 227

Group type: COMPARATOR
Intervention: Comparison of L-TAA and E-TAA
Number of subjects: 227
Study: 32360804

Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB)
Number of subjects: 21
Study: 32361007

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT guided adaptive radiation therapy (4 Gy boost on top of 70 Gy baseline dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT guided adaptive radiation therapy (78 Gy for partial metabolic response)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT guided adaptive radiation therapy (74 Gy for complete metabolic response)
Number of subjects: 20
Study: 32361755

Group type: EXPERIMENTAL
Intervention: Oral cabotegravir (30 mg/day)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks)
Number of subjects: 346
Study: 32361925

Group type: EXPERIMENTAL
Intervention: Coronary atherosclerotic plaque metrics and stenosis assessment
Number of subjects: 372
Study: 32361951

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 32362128

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) compliance measure (CCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient Exposure/Response Prevention Adherence Scale for Hoarding (PEAS-H)
Number of subjects: 0
Study: 32362164

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term use of COC
Number of subjects: 0
Study: 32363437

Group type: EXPERIMENTAL
Intervention: Subliminal micropulse yellow laser
Number of subjects: 29
Study: 32363493

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 909
Study: 32363545

Group type: EXPERIMENTAL
Intervention: Radial breast ultrasound (r-US)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Meander-like breast ultrasound (m-US)
Number of subjects: 148
Study: 32363605

Group type: EXPERIMENTAL
Intervention: Anxiety cluster
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Apathy/Withdrawal cluster
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Anxiety and Circadian Disturbance clusters
Number of subjects: 250
Study: 32363771

Group type: EXPERIMENTAL
Intervention: adalimumab-adbm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Humira
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching from Humira to adalimumab-adbm
Number of subjects: 0
Study: 32363910

Group type: EXPERIMENTAL
Intervention: Six-month ART dispensing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Three-month ART dispensing
Number of subjects: 18
Study: 32363949

Group type: EXPERIMENTAL
Intervention: Patients without CAV at 1 year and nonprogression over time
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Patients without CAV at 1 year and late-onset slow CAV progression
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Patients with mild CAV at 1 year and mild progression over time
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Patients with mild CAV at 1 year and accelerated progression
Number of subjects: 1301
Study: 32364230

Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 15022

Group type: EXPERIMENTAL
Intervention: Peanut oil
Number of subjects: 15022

Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 15022

Group type: EXPERIMENTAL
Intervention: Canola oil
Number of subjects: 15022

Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 15022

Group type: EXPERIMENTAL
Intervention: Refined blended plant oil
Number of subjects: 15022

Group type: COMPARATOR
Intervention: Substituting 1 tablespoon/d (8 g · 2000 kcal-1 · d-1) of soybean oil
Number of subjects: 15022
Study: 32364251

Group type: COMPARATOR
Intervention: Alarms
Number of subjects: 5983

Group type: COMPARATOR
Intervention: Code-word alarms
Number of subjects: 5983

Group type: COMPARATOR
Intervention: Alarm plus desmopressin
Number of subjects: 5983

Group type: COMPARATOR
Intervention: Alarm plus dry-bed training
Number of subjects: 5983
Study: 32364508

Group type: EXPERIMENTAL
Intervention: App version of the distress thermometer (DT)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: App version of the International Physical Activity Questionnaire (IPAQ)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: App version of the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: App version of the PHQ (Q10)
Number of subjects: 106
Study: 32364512

Group type: EXPERIMENTAL
Intervention: Exergames (serious games for physical exercise) delivered to patients' homes during home study phases 2 and 3.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E-coaching techniques implemented in home study phase 3.
Number of subjects: 28
Study: 32364602

Group type: EXPERIMENTAL
Intervention: Sleep restriction with circadian disruption (SRCD)
Number of subjects: 9
Study: 32364844

Group type: EXPERIMENTAL
Intervention: 400 mg spartalizumab intravenously, once every 4 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PD-L1 positive patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PD-L1 negative patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PD-L1 ≥ 50% patients
Number of subjects: 42
Study: 32365189

Group type: EXPERIMENTAL
Intervention: PCV-free HRV
Number of subjects: 1612

Group type: COMPARATOR
Intervention: HRV
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: PCV-free HRV and HRV
Number of subjects: 1612
Study: 32366122

Group type: EXPERIMENTAL
Intervention: Minimally invasive periacetabular osteotomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 64
Study: 32366324

Group type: EXPERIMENTAL
Intervention: 20% albumin infusion at 3 mL/kg over 30 min
Number of subjects: 30
Study: 32366486

Group type: EXPERIMENTAL
Intervention: External heated humidification during non-invasive ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no heated humidification)
Number of subjects: 0
Study: 32367136

Group type: EXPERIMENTAL
Intervention: Exercisers (n=57)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Non-exercisers (n=120)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Body mass index between 25 and 29.9
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Body mass index >30
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Physically strenuous occupations
Number of subjects: 177
Study: 32367609

Group type: EXPERIMENTAL
Intervention: Anal acoustic reflectometry (AAR) before and after rectal distension with 100 ml of air
Number of subjects: 32
Study: 32367616

Group type: EXPERIMENTAL
Intervention: Periodontally healthy individuals
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Gingivitis individuals
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Periodontitis individuals
Number of subjects: 750
Study: 32367815

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily in combination with sofosbuvir 400 mg for 12 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily
Number of subjects: 17
Study: 32368162

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir 50 mg/100 mg once daily for 12 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by open-label elbasvir/grazoprevir for 12 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 32368217

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with a single preseason booster of 1000 SQ-U Alutard 5-grasses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intralymphatic immunotherapy (ILIT) with standard dosing of 3000 SQ-U over 2 months
Number of subjects: 0
Study: 32368624

Group type: EXPERIMENTAL
Intervention: [18F] HX4 PET imaging during RTx
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: [18F] HX4 PET imaging with residual hypoxia (rHV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Static [18F] HX4 PET imaging
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Change in [18F] HX4 uptake
Number of subjects: 34
Study: 32368692

Group type: EXPERIMENTAL
Intervention: Mirabegron (a β3AR agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32368702

Group type: EXPERIMENTAL
Intervention: Robotic PVHR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open PVHR
Number of subjects: 100
Study: 32368713

Group type: EXPERIMENTAL
Intervention: self-management + text message program
Number of subjects: 100
Study: 32368793

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 4507

Group type: EXPERIMENTAL
Intervention: DBT
Number of subjects: 4507

Group type: EXPERIMENTAL
Intervention: MBT
Number of subjects: 4507
Study: 32368961

Group type: EXPERIMENTAL
Intervention: FDG PET/MRI
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Whole-body DW MRI
Number of subjects: 56
Study: 32368963

Group type: EXPERIMENTAL
Intervention: CT metrics of emphysema, venous vascular volume, and sarcopenia
Number of subjects: 0
Study: 32369480

Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg daily for 3 days
Number of subjects: 10
Study: 32369811

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Gastric Bypass (GB)
Number of subjects: 113

Group type: COMPARATOR
Intervention: SG
Number of subjects: 113

Group type: COMPARATOR
Intervention: GB
Number of subjects: 113
Study: 32370248

Group type: EXPERIMENTAL
Intervention: Right ventricular free wall longitudinal strain (RV FWS)
Number of subjects: 0
Study: 32370805

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes Healthy Diet Score
Number of subjects: 3268

Group type: COMPARATOR
Intervention: Healthy Diet Score
Number of subjects: 3268
Study: 32370854

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 154324

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 154324

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 154324

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 154324
Study: 32371459

Group type: EXPERIMENTAL
Intervention: CCR5 blockade
Number of subjects: 1330

Group type: COMPARATOR
Intervention: High CCR5 expression
Number of subjects: 1330
Study: 32371510

Group type: EXPERIMENTAL
Intervention: Malaria control tools usage
Number of subjects: 48448

Group type: EXPERIMENTAL
Intervention: Bed-net usage
Number of subjects: 48448

Group type: EXPERIMENTAL
Intervention: Inpatient discharges due to malaria
Number of subjects: 48448

Group type: EXPERIMENTAL
Intervention: Inpatient discharges due to HIV
Number of subjects: 48448

Group type: EXPERIMENTAL
Intervention: Inpatient discharges due to anaemia
Number of subjects: 48448
Study: 32371540

Group type: EXPERIMENTAL
Intervention: sorafenib, 400 mg twice daily
Number of subjects: 165
Study: 32371584

Group type: EXPERIMENTAL
Intervention: Prexasertib combined with cisplatin and radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin and radiation alone
Number of subjects: 0
Study: 32371667

Group type: EXPERIMENTAL
Intervention: Radiotherapy for cancer
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Nausea during treatment
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Poor sleep
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Management of nausea
Number of subjects: 196
Study: 32371801

Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Reduced sedentary time
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Decreased obesity
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Decreased insulin resistance
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Having triglycerides above 150 mg/dl
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Increased uric acid
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Insulin resistance index homeostatic model assessment
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Less physical activity
Number of subjects: 501
Study: 32371806

Group type: EXPERIMENTAL
Intervention: Hypertensive participants
Number of subjects: 535

Group type: COMPARATOR
Intervention: Normotensive participants
Number of subjects: 535
Study: 32372280

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 151
Study: 32372294

Group type: EXPERIMENTAL
Intervention: ER ambroxol 75-mg retard capsules once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: IR ambroxol 60-mg effervescent tablets twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: IR ambroxol 30-mg tablets twice daily
Number of subjects: 24
Study: 32372382

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 4849

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 4849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4849

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (both doses)
Number of subjects: 4849
Study: 32372416

Group type: EXPERIMENTAL
Intervention: DLL3-targeting antibody-drug conjugate (Rovalpituzumab tesirine - Rova-T)
Number of subjects: 65

Group type: COMPARATOR
Intervention: DLL3 expression
Number of subjects: 65
Study: 32372672

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor, sintilimab, administered for three cycles.
Number of subjects: 1
Study: 32373032

Group type: EXPERIMENTAL
Intervention: Online guided self-help intervention
Number of subjects: 99
Study: 32373059

Group type: EXPERIMENTAL
Intervention: Motor outcome measures, specific details not available
Number of subjects: 0
Study: 32373171

Group type: EXPERIMENTAL
Intervention: Spa treatment with radon water
Number of subjects: 0
Study: 32373366

Group type: EXPERIMENTAL
Intervention: Early cervical spine stabilizer (ECS) training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 40
Study: 32373649

Group type: EXPERIMENTAL
Intervention: rQNestin34.5v.2
Number of subjects: 0

Group type: COMPARATOR
Intervention: cyclophosphamide (CPA)
Number of subjects: 0
Study: 32374193

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32374423

Group type: EXPERIMENTAL
Intervention: Monthly injection of anti-VEGF agents (ranibizumab 0.5 mg, bevacizumab 1.25 mg, aflibercept 2.0 mg)
Number of subjects: 7732

Group type: COMPARATOR
Intervention: Standard PRN regimen
Number of subjects: 7732

Group type: COMPARATOR
Intervention: Treat-and-extend regimen
Number of subjects: 7732

Group type: COMPARATOR
Intervention: Standard PRN treatment
Number of subjects: 7732

Group type: EXPERIMENTAL
Intervention: Monthly injection
Number of subjects: 7732

Group type: EXPERIMENTAL
Intervention: Monthly injections
Number of subjects: 7732

Group type: COMPARATOR
Intervention: PRN regimens
Number of subjects: 7732

Group type: COMPARATOR
Intervention: Extended-fixed regimen
Number of subjects: 7732

Group type: EXPERIMENTAL
Intervention: Monthly group
Number of subjects: 7732

Group type: COMPARATOR
Intervention: Extended-fixed group
Number of subjects: 7732
Study: 32374868

Group type: EXPERIMENTAL
Intervention: Post gadolinium arterial wall enhancement (AWE) on MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical and imaging follow-up without occlusion treatment
Number of subjects: 0
Study: 32374962

Group type: EXPERIMENTAL
Intervention: Emapalumab with dexamethasone
Number of subjects: 34
Study: 32375659

Group type: EXPERIMENTAL
Intervention: Positive framing of results in CSR PLSs (Trial 1)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Negative framing of results in CSR PLSs (Trial 1)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Natural frequencies for presentation of results in CSR PLSs (Trial 2)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Percentages for presentation of results in CSR PLSs (Trial 2)
Number of subjects: 336
Study: 32375680

Group type: EXPERIMENTAL
Intervention: Spline-based models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard and spline-based parametric models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goodness-of-fit scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hazard-based plots and goodness-of-fit tests
Number of subjects: 0
Study: 32375690

Group type: EXPERIMENTAL
Intervention: Somatic tumor genomic testing
Number of subjects: 58
Study: 32375700

Group type: EXPERIMENTAL
Intervention: 60s continuous walking performance parameters
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gait performance parameters from continuous walking
Number of subjects: 126
Study: 32375779

Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Moderate+vigorous physical activity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 102
Study: 32375814

Group type: EXPERIMENTAL
Intervention: Transcatheter rectal arterial chemoembolization (TRACE) with oxaliplatin and S-1 concurrent chemoradiotherapy (NATRACE-CRT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard fluorouracil-based combined modality treatment (NA-CRT)
Number of subjects: 95
Study: 32375872

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) treatment
Number of subjects: 10
Study: 32376136

Group type: EXPERIMENTAL
Intervention: Nivolumab with recent ATB use (n=11; 16%)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nivolumab without recent ATB use
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nivolumab with fecal transplant (FMT) from responding RCC patients or beneficial commensals (Akkermansia muciniphila and Bacteroides salyersiae)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nivolumab with prior TKI exposure
Number of subjects: 69
Study: 32376304

Group type: EXPERIMENTAL
Intervention: S-ICD in patients on HD (group 1)
Number of subjects: 220

Group type: COMPARATOR
Intervention: S-ICD in patients not on HD (group 2)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: S-ICD in both groups
Number of subjects: 220
Study: 32376325

Group type: EXPERIMENTAL
Intervention: STOPBANG screening approach
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Multivariable Apnea Prediction Index (MAPI)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Portable diagnostic approach
Number of subjects: 214

Group type: COMPARATOR
Intervention: Laboratory-quality polysomnography
Number of subjects: 214

Group type: COMPARATOR
Intervention: Portable testing
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: MAPI
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: STOPBANG
Number of subjects: 214

Group type: COMPARATOR
Intervention: Initial assessment with polysomnography
Number of subjects: 214
Study: 32376335

Group type: EXPERIMENTAL
Intervention: Real-time AI-assisted detection
Number of subjects: 52
Study: 32376721

Group type: EXPERIMENTAL
Intervention: Ipilimumab and GM-CSF in metastatic melanoma patients
Number of subjects: 51
Study: 32376795

Group type: EXPERIMENTAL
Intervention: PPSV23 vaccination in obese participants (BMI ≥30 kg/m2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: PPSV23 vaccination in nonobese participants (BMI 22-25 kg/m2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PPSV23 vaccination in WT STING1 group (R232/R232)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PPSV23 vaccination in obese participants with 1 HAQ allele
Number of subjects: 46
Study: 32377266

Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Active Control Intervention
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 21
Study: 32377287

Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient clinic therapy
Number of subjects: 0
Study: 32377367

Group type: EXPERIMENTAL
Intervention: Nationwide retrieval project for LTFU patients with chronic hepatitis C
Number of subjects: 0
Study: 32377804

Group type: EXPERIMENTAL
Intervention: Total sugar intake (100 kcal increase per day)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Total sugar from sweetened beverages (100 kcal)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Total sugar from milk products (100 kcal)
Number of subjects: 325
Study: 32377892

Group type: EXPERIMENTAL
Intervention: Children with cardiac disease (CCD)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 56
Study: 32377963

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 877
Study: 32377978

Group type: EXPERIMENTAL
Intervention: DFP-11207, administered orally daily, doses escalating from 40 mg/m²
Number of subjects: 0
Study: 32378735

Group type: COMPARATOR
Intervention: Antenatal PFMT
Number of subjects: 10832

Group type: COMPARATOR
Intervention: PFMT started after delivery
Number of subjects: 10832

Group type: COMPARATOR
Intervention: Postnatal PFMT
Number of subjects: 10832
Study: 32379042

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 133